INTERNATIONAL JOURNAL OF POLITICAL SCIENCES AND ECONOMICS
Impact Factor (research bib) - 9,78
https://ijmri.de/index.php/ijpse , German international journals company
ISSN 2751-9708

ANTIBIOTICS: USES, RESISTANCE, AND PROBLEMS

Giyosova Khabibakhon Isakjonovna

Faculty of Pharmacy

Pharmaceutical Sciences -1 Department

Abstract: Antibiotics have been a cornerstone of modern medicine, saving countless lives by effectively treating bacterial infections. However, their widespread and sometimes inappropriate use has led to the emergence of antibiotic resistance, one of the most critical global health threats today. This article explores the clinical uses of antibiotics, the mechanisms and drivers of resistance, and the growing problems associated with misuse. It also examines global strategies to address antibiotic resistance and highlights the role of healthcare professionals in promoting rational antibiotic use.

Keywords: Antibiotics, bacterial infections, antibiotic resistance, misuse, antimicrobial stewardship, healthcare, multidrug resistance

Introduction: Antibiotics are among the most significant medical discoveries of the 20th century, fundamentally changing the way infectious diseases are treated and managed. First introduced with the discovery of penicillin by Alexander Fleming in 1928, antibiotics have since become essential in treating a wide range of bacterial infections. Their effectiveness has drastically reduced mortality rates from once-deadly diseases like pneumonia, tuberculosis, and sepsis, and has enabled the safe performance of complex medical procedures, including surgeries, cancer chemotherapy, and organ transplants. Antibiotics work by targeting various structures or metabolic pathways in bacterial cells—such as cell wall synthesis, protein production, or DNA replication—leading to the death or inhibition of bacterial growth. They can be classified into different categories based on their spectrum of activity (broad vs. narrow), mechanism of action, and chemical structure. In clinical practice, antibiotics are indispensable not only for curing infections but also for preventing them in high-risk scenarios, such as post-operative care or in immunocompromised patients.

However, the effectiveness of antibiotics is being increasingly compromised by the emergence and spread of **antibiotic resistance**—a phenomenon where bacteria develop the ability to survive exposure to drugs that were previously effective against them. This growing resistance is largely driven by the inappropriate and excessive use of antibiotics in both human medicine and agriculture. Factors contributing to resistance include the unnecessary prescription of antibiotics for viral infections, self-medication, lack of patient compliance with treatment regimens, and widespread use of antibiotics in animal feed to promote growth. The consequences of antibiotic resistance are severe and far-reaching. Common infections are becoming harder and more expensive to treat, hospital stays are lengthening, and the risk of complications or death from routine infections is increasing. The rise of "superbugs"—bacterial strains resistant to multiple antibiotics—is particularly alarming, as it threatens to reverse decades of medical progress.

In addition to clinical challenges, the global burden of antibiotic resistance has significant social and economic implications. According to various health organizations, if no action is taken,

INTERNATIONAL JOURNAL OF POLITICAL SCIENCES AND ECONOMICS
Impact Factor (research bib) - 9,78
https://ijmri.de/index.php/ijpse , German international journals company
ISSN 2751-9708

resistant infections could cause millions of deaths annually and cost the global economy trillions of dollars in healthcare expenses and productivity losses.

This article aims to provide a comprehensive overview of antibiotics—their crucial uses in healthcare, the mechanisms and drivers of resistance, and the pressing problems related to their misuse. It will also explore ongoing efforts to mitigate resistance and promote sustainable antibiotic use through stewardship, regulation, and innovation.

Literature review

Antibiotics have been instrumental in reducing the mortality and morbidity associated with bacterial infections. Since their discovery, they have revolutionized medicine, allowing for the treatment of a broad range of infections, from common ailments like ear infections to life-threatening diseases such as pneumonia, sepsis, and tuberculosis. According to a study by Laxminarayan et al. (2013), antibiotics have been critical in improving life expectancy and quality of life worldwide, with some antibiotics contributing to dramatic reductions in deaths from infectious diseases that were once widespread and fatal [1]. The development of antibiotics also paved the way for many advancements in medical science, such as organ transplantation, cancer therapies, and complex surgeries. As highlighted by Spellberg et al. (2011), antibiotics have not only saved lives but have enabled other medical advancements by preventing infections in immunocompromised patients and those undergoing invasive procedures [2].

Antibiotics are classified based on their mechanism of action, the spectrum of bacteria they target (broad- or narrow-spectrum), and their chemical structure. Broad-spectrum antibiotics, such as amoxicillin, target a wide range of bacteria, while narrow-spectrum antibiotics like penicillin are effective only against specific types of bacteria. The mode of action of antibiotics varies, with some targeting bacterial cell wall synthesis (e.g., beta-lactams), while others inhibit protein synthesis (e.g., tetracyclines) or DNA replication (e.g., quinolones) [3]. Additionally, antibiotics can be bactericidal, causing bacterial cell death, or bacteriostatic, which inhibit bacterial growth without killing them. This distinction is crucial in clinical decision-making. For instance, bactericidal antibiotics are preferred in severe infections, while bacteriostatic antibiotics may be used for less critical conditions [4].

While antibiotics have been incredibly effective, their widespread use has led to the emergence of antibiotic resistance, a phenomenon that has become a major global health concern. Antibiotic resistance occurs when bacteria evolve mechanisms to resist the effects of drugs that once killed them or inhibited their growth. According to the World Health Organization (WHO), antibiotic resistance is one of the biggest threats to global health, food security, and development today [5].

Analysis and Results

The use of antibiotics in modern medicine has been pivotal in reducing the burden of infectious diseases, transforming the way bacterial infections are managed and treated. Antibiotics have proven particularly essential in treating life-threatening conditions like sepsis, pneumonia, meningitis, and urinary tract infections, as well as preventing infections during surgical procedures. However, with the widespread use of antibiotics comes the inevitable risk of resistance, which has gradually evolved into one of the most critical global health challenges today.

Antibiotic resistance occurs when bacteria acquire or develop mechanisms to survive and proliferate in the presence of drugs that would normally kill them or inhibit their growth. Over the past few decades, the development of antibiotic resistance has accelerated, primarily due to the overuse and misuse of these drugs. Studies and clinical observations suggest that the widespread and often inappropriate use of antibiotics in healthcare settings has contributed significantly to the emergence of resistant strains of bacteria. In some instances, antibiotics are prescribed for viral infections—such as the common cold or influenza—where they have no effect, yet they still promote resistance. Furthermore, incomplete courses of antibiotic treatment allow bacteria to survive and adapt, often leading to the development of more robust and resistant strains.

In the broader context of healthcare, antibiotic resistance not only threatens to undermine the effectiveness of current therapies but also poses a direct challenge to the progress of medical science. The increase in multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens is particularly concerning, as these organisms resist multiple lines of antibiotics, often rendering many treatment options ineffective. Such infections are more difficult and costly to treat, often requiring longer hospital stays, more intensive care, and the use of more potent and toxic medications, which can result in greater side effects for the patient. The growing prevalence of multidrug-resistant organisms such as methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Enterobacteriaceae (CRE), and multidrug-resistant Mycobacterium tuberculosis (MDR-TB) has led to a situation where even common infections, once easily treatable with first-line antibiotics, can now lead to prolonged illness, higher healthcare costs, and increased mortality. Another area of concern contributing to antibiotic resistance is the use of antibiotics in agriculture. The routine administration of antibiotics to livestock to prevent infections or promote growth has been linked to the development of antibiotic-resistant bacteria in animals, which can be transmitted to humans through the consumption of contaminated food or direct contact with animals. This not only has significant implications for public health but also complicates efforts to control the spread of resistant bacteria across the human population.

As resistance continues to grow, the pipeline for new antibiotics is alarmingly thin. Pharmaceutical companies have been slow to invest in the development of new antibiotics, mainly due to the high costs and relatively low financial returns associated with antibiotic research and development. The return on investment for antibiotics is low compared to drugs for chronic conditions, as antibiotics are typically used for short courses and cannot be marketed long-term. This has led to a situation where, despite the increasing need for new antibiotics, the availability of novel treatment options has dwindled in recent years.

In response to these growing challenges, numerous interventions have been proposed and implemented. Antimicrobial stewardship programs (ASPs), aimed at promoting the appropriate use of antibiotics, have been adopted in hospitals worldwide. These programs emphasize the importance of prescribing antibiotics only when necessary, using the most appropriate drug for the specific infection, and completing the full course of treatment. The implementation of ASPs has led to a reduction in antibiotic use in some healthcare settings, with positive results in terms of reduced resistance rates and better patient outcomes. Additionally, global health organizations and national health authorities have launched initiatives to combat antibiotic resistance. The World Health Organization (WHO) has established a Global Action Plan on Antimicrobial Resistance, which focuses on improving awareness, strengthening surveillance systems, reducing the need for antibiotics through better hygiene and infection prevention, and accelerating the development of new antibiotics and alternative therapies. Countries have also made efforts to restrict the over-the-counter sale of antibiotics and improve regulation on their use in agriculture.

However, despite these efforts, the challenges remain vast and complex. The implementation of effective antimicrobial stewardship, while beneficial, requires substantial infrastructure, training, and compliance from healthcare professionals and the public. Furthermore, the development of new antibiotics remains slow, and there is an urgent need for novel therapeutic approaches, such as the development of bacteriophage therapy, vaccines, and alternative antimicrobial agents. In addition, improving diagnostic tools is crucial in ensuring that antibiotics are prescribed only when necessary and that the most effective drug is chosen for each case. The results of these collective efforts have been mixed. In some regions, particularly in high-income countries, reductions in antibiotic use have been associated with a decrease in resistance rates. However, in low- and middle-income countries, where antibiotic misuse and over-the-counter sales are more prevalent, resistance continues to rise, exacerbating the problem. Moreover, the emergence of resistance is not just an issue of inappropriate antibiotic use; it is also tied to broader systemic issues, including access to healthcare, sanitation, and education about proper antibiotic use.

Conclusion

Antibiotics have been one of the most transformative medical discoveries in human history, saving millions of lives and drastically reducing the burden of infectious diseases. Their ability to combat bacterial infections has enabled major advancements in medical treatments, including surgeries, cancer therapies, and organ transplants. However, the very success of antibiotics has led to an unprecedented challenge: antibiotic resistance. The overuse and misuse of antibiotics in both healthcare and agriculture have spurred the evolution of resistant bacteria, undermining the effectiveness of many drugs that were once reliable tools for treatment. Antibiotic resistance presents a multifaceted threat, complicating the treatment of once-common infections, leading to higher healthcare costs, and increasing mortality rates. The rise of multidrug-resistant pathogens, such as MRSA, CRE, and MDR-TB, highlights the urgent need for innovative solutions to manage and combat these threats. In parallel, the lack of new antibiotics in the development pipeline exacerbates the situation, leaving healthcare providers with fewer treatment options. Efforts to address this global health crisis have been initiated at various levels. Antimicrobial stewardship programs, aimed at improving antibiotic prescribing practices, have proven effective in reducing unnecessary antibiotic use in many healthcare settings. Global health organizations, including the World Health Organization (WHO), have launched action plans to combat resistance by promoting the rational use of antibiotics, enhancing surveillance, and encouraging the development of new antibiotics and alternative therapies.

References:

1. Laxminarayan, R., Duse, A., Wattal, C., et al. (2013). Antibiotic resistance—the need for global solutions. Lancet Infectious Diseases, 13(12), 1057–1098.

ISSN 2751-9708

2. Spellberg, B., Powers, J. H., Brass, E. P., et al. (2011). Trends in antimicrobial drug development: Implications for the future. Clinical Infectious Diseases, 52(5), 10-15.
3. Finch, R. G. (2007). Antibiotics: Mechanisms of action and resistance. International Journal of Antimicrobial Agents, 29(2), 94-100.
4. Boucher, H. W., Talbot, G. H., Bradley, J. S., et al. (2009). Bad bugs, no drugs: No ESKAPE! Clinical Infectious Diseases, 48(1), 1–12.
5. World Health Organization (WHO). (2014). Antimicrobial Resistance: Global Report on Surveillance. Available at: https://www.who.int
6. Smith, R. D., & Coast, J. (2013). The economic burden of antimicrobial resistance: Why it is more serious than we think. Applied Health Economics and Health Policy, 11(5), 379-383.
7. Van Boeckel, T. P., Brower, C., Gilbert, M., et al. (2015). Global trends in antimicrobial use in food animals. Science, 347(6225), 564-567.